Effect of Preoperative Aspirin in Patients Undergoing Off-pump Coronary Artery Bypass Grafting

Medinet Heart Centre

Status and phase: Unknown; Phase 4

Conditions: Coronary Artery Disease; Aspirin

Treatments: Drug: vitamin C; Drug: Aspirin

Study type: Interventional

Funder types: Other

Identifiers

NCT03049085

Preoperative aspirin-OPCAB

Details and patient eligibility

About

Effect of Preoperative Aspirin in patients undergoing Off-pump Coronary Artery Bypass Grafting. A double-blind, placebo-controlled, randomized trial.

Enrollment: 300 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Eligible patients undergoing off-pump coronary artery bypass grafting (OPCAB)
• Patients in whom antiplatelet therapy was stopped 5-7 days prior to OPCAB

Exclusion criteria

• Patients undergoing on-pump coronary artery bypass grafting
• Patients in whom antiplatelet therapy was not stopped 5-7 days prior to OPCAB
• Intraoperative conversion to on-pump coronary artery bypass grafting
• Patients with inherited blood-clotting disorders
• Patients undergoing other cardiac operations

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

300 participants in 2 patient groups, including a placebo group

Aspirin group

Active Comparator group

Description:

a 75 mg uncoated aspirin is administered 2 hours prior to OPCAB

Treatment:

Drug: Aspirin

Placebo group

Placebo Comparator group

Description:

75 mg Vit. C is administered 2 hours prior OPCAB

Treatment:

Drug: vitamin C